

# GI adverse events up with GLP-1 receptor agonists

November 16 2016

---



(HealthDay)—Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs)

are associated with increased risk of gastrointestinal adverse events (AEs), with risk varying based on dose, background medications, and type of GLP-1 RA, according to research published online Nov. 9 in *Diabetes, Obesity and Metabolism*.

Karolin Bettge, from St. Josef Hospital in Bochum, Germany, and colleagues conducted a systematic literature review and selected 32 phase 3 clinical trials with GLP-1 RAs. They analyzed the proportion of patients reporting nausea, vomiting, or diarrhea for different doses and glucose-lowering background medications.

The researchers observed a dose-dependent risk for nausea for long-acting agents and across all GLP-1 RAs ( $P = 0.0063$  and  $0.0017$ , respectively); a similar trend was seen for vomiting ( $P = 0.23$ ). There was a dose-dependent risk for diarrhea ( $P = 0.031$ ). More nausea and vomiting were seen for background treatment with metformin ( $P = 0.04$  and  $0.0009$ , respectively). Less nausea and less diarrhea were seen for lixisenatide versus exenatide (twice/day). The risk was similar for dulaglutide and liraglutide, while less risk was seen for exenatide and albiglutide versus liraglutide. Compared with short-acting agents, long-acting GLP-1 RAs correlated with less [nausea](#) and [vomiting](#) but more [diarrhea](#).

"GLP-1 RAs are associated with gastrointestinal AEs that are related to dose and background medications (especially metformin), and may vary in a compound-specific manner," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

**More information:** [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: GI adverse events up with GLP-1 receptor agonists (2016, November 16) retrieved 24 April 2024 from <https://medicalxpress.com/news/2016-11-gi-adverse-events-glp-receptor.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.